RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Associations between avoidant/restrictive food intake disorder dimensions and obsessive-compulsive symptomatology
Aguilar, M. V., Giulumian, G. K., Rodriguez, I., Baker, J. H., Surti, P. P., Dinkler, L., Guintivano, J., Johnson, J. S., MacDermod, C. M., Ortiz, S. N., Pisetsky, E. M., White, J. P., Micali, N., Bulik, C. M., Thornton, L. M., & Wu, Y.-K. (2026). Associations between avoidant/restrictive food intake disorder dimensions and obsessive-compulsive symptomatology. European Eating Disorders Review, 34(5), 1327-1335. https://doi.org/10.1002/erv.70122
OBJECTIVE: Although obsessive-compulsive disorder (OCD) commonly co-occurs with anorexia nervosa and bulimia nervosa, less is known about its relationship with avoidant/restrictive food intake disorder (ARFID) dimensions. Whether associations between ARFID dimensions and OCD differ by sex is also unclear. We examined associations between ARFID dimensions and OCD symptoms by sex, accounting for depression and anxiety.
METHODS: Data from 3120 participants ages 15+ in the ARFID Genes and Environment (ARFID-GEN) study were analyzed. ARFID dimensions (i.e., sensory sensitivity; low appetite/lack of interest in food; and fear of aversive consequences), OCD symptoms, anxiety, and depression were assessed using validated self-report measures. We evaluated associations between ARFID dimensions and OCD symptoms using general linear models, adjusting for depression and anxiety.
RESULTS: ARFID dimensions were significantly associated with OCD symptoms. After adjusting for depression and anxiety, these associations were attenuated but remained significant for all ARFID dimensions. Associations between ARFID dimensions and OCD symptoms varied by sex.
CONCLUSION: The relation between ARFID symptomatology and OCD warrants further exploration across the developmental spectrum in which ARFID appears. Clinically, bidirectional screening may improve diagnostic clarity and be informative to tailor interventions appropriately.
TRIAL REGISTRATION: ARFID-GEN is registered in clinicaltrials.gov (NCT05605067).
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.
